Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aileron Therapeutics Inc | ALRN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.52 | 04:17:06 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.52 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.12 - 5.64 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.52 | USD |
Aileron Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.9M | 4.54M | - | 0 | -27.33M | -6.02 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aileron Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALRN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.52 | 1.59 | 1.4177 | 1.50 | 9,307 | 0.00 | 0.0% |
| 1 Month | 1.68 | 1.76 | 1.4177 | 1.56 | 11,478 | -0.16 | -9.52% |
| 3 Months | 1.94 | 2.0902 | 1.4177 | 1.71 | 16,496 | -0.42 | -21.65% |
| 6 Months | 1.29 | 2.1349 | 1.12 | 1.64 | 20,971 | 0.23 | 17.83% |
| 1 Year | 4.20 | 5.64 | 1.12 | 3.38 | 86,899 | -2.68 | -63.81% |
| 3 Years | 25.20 | 49.40 | 1.12 | 24.56 | 783,560 | -23.68 | -93.97% |
| 5 Years | 55.80 | 61.98 | 1.12 | 23.55 | 641,583 | -54.28 | -97.28% |
Aileron Therapeutics Description
| Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. |